


AETIONOMY

Generating a mechanism-based taxonomy of Alzheimer's and Parkinson's disease and validating in the course of a prospective clinical trial

VISION AND PARTNERSHIP

Vision

- Diseases are defined largely on the basis of their symptoms leading to the same diagnosis, although the underlying causes of their symptoms may be very different. This means that a treatment that works in one patient may prove ineffective in another one. A new approach to disease classification is needed, and that is where the AETIONOMY project comes in towards a new approach to the classification of neurodegenerative diseases – increasing chances for Alzheimer's and Parkinson's patients to receive personalized diagnosis and treatment.



Public-private Partnership in Life Sciences

- Collaboration between key players involved in healthcare research, including universities, research centers, the pharmaceutical industries, and patient organizations

- Pharmaceutical industries – Business



- Research – Academia



- Clinics – Health care



- Patient interests – Ethics and law



www.aetionomy.eu



The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under AETIONOMY grant agreement n°115568, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution.

www.imi.europa.eu